Furthermore, by inhibiting the activation of the Ras/Raf/MEK/ERK/MAPK and PI3K/AKT/mTOR pathways, lactate production, and tumor cell survival can be reduced, enhancing the therapeutic efficacy of ADCs (Figure 4). The gene discussed is AKT1; the disease is neoplasm.